Clinical Research Directory

Inclusion Criteria: * Age \> 18 and \< 80 years * Histologically confirmed adenocarcinoma of the prostate initial diagnosis * History of a previous adjuvant/salvage RT following prostatectomy or curative RT * Diagnosis of local recurrence at the restaging imaging in hormone sensitive patients (maximum 1 prostate bed recurrence and 3 intraprostatic recurrences) * DICOM plan of the previous RT course * No evidence of greater than grade 2 according to Common Terminology Criteria for Adverse Events (CTCAE) genitourinary (GU) or gastrointestinal (GI) late adverse events from the previous RT course * Eastern Cooperative Oncology Group (ECOG) Performance Status \<2 * Good urinary flow (peak flow \>10 mL/s) or IPSS \< 15 * Written informed consent for treatment and research purpose Exclusion Criteria: * Evidence of distant metastasis at the restaging imaging * Patients with current concomitant anticoagulant therapy (antiplatelet therapy is allowed even if it will be temporary suspended before fiducials implant) * Platelets count \< 75'000/uL * Urethral stricture * Having received previous different salvage treatments for PCa local relapse * Development of BCR while on ADT * Concomitant inflammatory bowel disease or other serious systemic comorbidities * Presence of hip prosthesis * Impossibility of performing an MRI